Isthmus Partners, LLC Amgen Inc Transaction History

Isthmus Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$218.65 - $271.46 $174,920 - $217,167	800 New	800 $215,000
Q4 2022 Feb 10, 2023	BUY	$229.03 - $291.01 $183,224 - $232,808	800 New	800 $210,000
Q3 2021 Nov 10, 2021	SELL	$212.27 - $248.7 $169,816 - $198,960	-800 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$233.58 - $259.14 $186,864 - $207,312	800 New	800 $195,000
Q4 2020 Feb 16, 2021	SELL	$216.38 - $257.67 $173,104 - $206,136	-800 Closed	0 $0
Q3 2020 Nov 04, 2020	BUY	$234.65 - $260.95 $187,720 - $208,760	800 New	800 $203,000
Q2 2019 Aug 09, 2019	SELL	$166.7 - $195.41 $3.31 Million - $3.88 Million	-19,871 Closed	0 $0
Q1 2019 Apr 19, 2019	BUY	$180.87 - $203.88 $3.59 Million - $4.05 Million	19,871 New	19,871 $936,000
Q4 2018 Feb 04, 2019	SELL	$178.4 - $208.25 $142,720 - $166,600	-800 Closed	0 $0
Q1 2018 May 11, 2018	SELL	$169.43 - $198.0 $13,384 - $15,642	-79 Reduced 8.99%	800 $136,000
Q3 2017 Nov 02, 2017	BUY	$167.29 - $191.0 $147,047 - $167,889	879	879 $164,000

3,123

409M

7.56M

7.2M

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $146B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

Get notified when there are updates to the investment portfolio of Isthmus Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Isthmus Partners, LLC with notifications on news.